Alzheimer's blood tests near routine use; early diagnosis shifts care paradigm

New blood-based biomarkers for Alzheimer's disease are advancing toward routine clinical adoption, enabling diagnosis years before symptom onset. The technology's accuracy and clinical utility remain under evaluation, but early detection could reshape patient management and drug trial design. This marks a notable step in neurodegenerative disease diagnostics, though widespread implementation and reimbursement are uncertain.